Table 1.
Patient characteristics and demographics*
| Characteristic | NC cohort | All patients |
|---|---|---|
| (n = 19) | (n = 65) | |
| Age, y | ||
| Mean (SD) | 31.5 (13.0) | 50.7 (17.4) |
| Median (range) | 27.0 (17–61) | 54.0 (17–86) |
| Female sex, no. (%) | 10 (53) | 31 (48) |
| ECOG performance status, no. (%) | ||
| 0 | 4 (21) | 22 (34) |
| 1 | 12 (63) | 40 (62) |
| 2 | 3 (16) | 3 (5) |
| ≥3 | 0 | 0 |
| Primary tumor type, no. (%) | ||
| Colon or rectum | — | 22 (34) |
| NC | 19 (100) | 19 (29) |
| Prostate | — | 9 (14) |
| Small cell lung | — | 6 (9) |
| Breast | — | 5 (8) |
| Non-small cell lung | — | 2 (3) |
| Neuroblastoma | — | 1 (2) |
| Multiple myeloma | — | 1 (2) |
| Time since initial diagnosis, median (range), d† | 95 (26–318) | 725 (26–5667) |
| Time since last progression, median (range), d‡ | 40 (9–177) | 45 (5–359) |
| Metastatic disease at screening, no. (%)§ | 15 (79) | 60 (94) |
| Prior cancer-related therapy, no. (%) | ||
| Surgery | 12 (63) | 44 (68) |
| Radiotherapy | 12 (63) | 41 (63) |
| Prior systemic therapy lines, no. (%) | ||
| 0 | 4 (21) | 4 (6) |
| 1 | 9 (47) | 10 (15) |
| 2 | 4 (21) | 5 (8) |
| ≥3 | 2 (11) | 46 (71) |
*
Due to some instances of missing dates, durations could not be calculated for all patients. ECOG = Eastern Cooperative Oncology Group; NC = NUT carcinoma; NUT = nuclear protein in testis.
†
NC: n = 18, total: n = 57.
‡
NC: n = 9, total: n = 51.
§
NC: n = 19, total: n = 64.